Inhibitors of Drp1-filamin complex formation
Novel Drp1-filamin complex inhibitors, such as those represented by formulas (I), (1), (2), (A), and (B), address the limitations of existing treatments by selectively inhibiting mitochondrial fission and reducing calcium channel blocking, providing therapeutic benefits for conditions like chronic heart failure and diabetes.
Patent Information
- Application Number
- JP2023069650
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-05-31
- Filing Date
- 2023-04-20
- Publication Date
- 2024-11-20
- Estimated Expiration
- 2040-05-26
AI Technical Summary
Existing treatments for conditions associated with Drp1-filamin complex formation, such as mitochondrial dysfunction, lack effective inhibitors that can selectively target this complex without significant calcium channel blocking effects, limiting their therapeutic applicability, especially for non-hypertensive patients.
Development of novel compounds, including those represented by formulas (I), (1), (2), (A), and (B), which inhibit Drp1-filamin complex formation with varying abilities to suppress mitochondrial fission while minimizing calcium channel blocking, offering enhanced therapeutic potential for conditions like chronic heart failure, amyotrophic lateral sclerosis, and diabetes.
These compounds effectively inhibit mitochondrial fission and promote therapeutic benefits for Drp1-related diseases, including improved survival rates and reduced mitochondrial dysfunction, without the hypotensive effects of existing drugs like cilnidipine.
Smart Images

Figure 0007587300000089 
Figure 0007587300000090 
Figure 0007587300000091
Abstract
Description
[Technical field]
[0001] The present invention relates to dynamin-related protein 1 (Drp1)-filamin complex formation inhibitors and novel compounds. [Background technology]
[0002] Mitochondria are organelles found in almost all eukaryotic cells and are mainly involved in ATP production as a result of oxidative phosphorylation occurring in the electron transport chain. Mitochondria undergo repeated fusion and fission, and their abnormalities are known to be involved in the development of cancer, cardiovascular disease, neurodegenerative diseases, and other conditions. For example, it has been suggested that mitochondrial morphological dysfunction induced in the non-infarcted area after myocardial infarction causes energy metabolism disorders and leads to chronic heart failure.
[0003] Abnormal interactions between mitochondria and the actin cytoskeleton have attracted public attention as an important determinant of cardiac vulnerability after myocardial infarction. Mitochondrial fission is induced by activation of Drp1, a GTP-binding protein. The present inventors have demonstrated that upon hypoxic stimulation of cardiomyocytes, intracellular Drp1 binds filamin to form a Drp1-filamin complex, which in turn forms a Drp1-filamin-actin complex to activate itself and promote mitochondrial fission. The present inventors have also demonstrated that cilnidipine inhibits the formation of the Drp1-filamin complex. (See, for example, Non-Patent Document 1.)
[0004] Cilnidipine is a compound represented by the following chemical formula (A1). Cilnidipine blocks L-type calcium channels and N-type calcium channels, and has been used as an antihypertensive drug. Cilnidipine is characterized by its sustained antihypertensive effect compared to other antihypertensive drugs. Therefore, cilnidipine is useful as a therapeutic drug for cardiovascular diseases such as heart failure and arrhythmia (see, for example, Patent Document 1).
[0005] [ka] [Prior art documents] [Patent documents]
[0006] [Patent Document 1] International Publication No. 2016 / 080516 [Non-patent literature]
[0007] [Non-Patent Document 1] Nishimura A., et al., Hypoxia-induced interaction of filamin with Drp1 causes mitochondrial hyperfission-associated myocardial senescence, Sci.Signal., 11(556), eaat5185, 2018. Summary of the Invention [Problem to be solved by the invention]
[0008] An object of the present invention is to provide a Drp1-filamin complex formation inhibitor and a novel compound that can be included as an active ingredient in a Drp1-filamin complex formation inhibitor. [Means for solving the problem]
[0009] The present invention includes the following aspects.
[0010] In one aspect, the present invention provides a compound of formula (I): [ka] and its pharmacologically acceptable salts and solvates thereof, During the ceremony, The compound is [ka] If other than, R 1 is phenyl substituted with 1 to 3 substituents, each of which is independently NO2, NH2, OH, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 alkoxyalkyl, with the proviso that at least one substituent is NO2 or NH2; R 2 is H, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 alkoxyalkyl; R 3 is H, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 alkoxyalkyl; R 4 is C1-C6 alkyl or C1-C6 haloalkyl; R 5 is phenyl or pyridinyl, wherein the phenyl or pyridinyl is unsubstituted or substituted with 1 to 3 substituents, each of which is independently NO2, NH2, OH, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 alkoxyalkyl; (i) bond a is present and bonds b and c are absent, or (ii) bonds b and c are present and bond a is absent, A is NH when bond a is present, and N when bonds b and c are present; m is an integer from 1 to 4; n is an integer from 1 to 3. Compounds of formula (I) are further described in the detailed description and specific embodiments 1-41 below.
[0011] In another aspect, the present invention provides a compound of formula (1): [ka] and its pharmacologically acceptable salts and solvates thereof, During the ceremony, R 1 represents a phenyl group, a 2-pyridyl group, a 3-pyridyl group, or a 4-pyridyl group; R 2represents a hydrogen atom or an amino group, R 3 represents a hydrogen atom or a nitro group, R 2 is a hydrogen atom, R 3 is a nitro group, and R 2 is an amino group, R 3 is a hydrogen atom. Compounds of formula (I) are further described in the detailed description below and in specific embodiments 42-44.
[0012] In another aspect, the present invention provides a compound of formula (2): [ka] and its pharmacologically acceptable salts and solvates thereof, During the ceremony, R 4 represents a phenyl group, a 2-pyridyl group, a 3-pyridyl group, or a 4-pyridyl group; R 5 represents an amino group, and R 6 represents a hydrogen atom.
[0013] In another aspect, the present invention provides a compound of formula (A): [ka] and its pharmacologically acceptable salts and solvates thereof, During the ceremony, The compound is [ka] If other than, R is NO2 or NH2, R is in the 2-, 3-, or 4-position of the phenyl ring, and X is CH or N.
[0014] In another aspect, the present invention provides a compound of formula (B): [ka] and its pharmacologically acceptable salts and solvates thereof, During the ceremony, R is NO2 or NH2, R is in the 2-, 3-, or 4-position of the phenyl ring, and X represents CH or N.
[0015] In another aspect, the present invention includes a pharmaceutical composition comprising (a) a compound of the present invention and (b) one or more pharma- ceutically acceptable carriers. As used herein, the term "compound of the present invention" refers to a compound of formula (I) or a pharmacologically acceptable salt or solvate thereof, a compound of formula (1) or a pharmacologically acceptable salt or solvate thereof, a compound of formula (2) or a pharmacologically acceptable salt or solvate thereof, a compound of formula (A) or a pharmacologically acceptable salt or solvate thereof, or a compound of formula (B) or a pharmacologically acceptable salt or solvate thereof. The above pharmaceutical compositions, sometimes referred to herein as "pharmaceutical compositions of the present invention", are further described below in the detailed description and in specific embodiments 65-88.
[0016] In another aspect, the present invention includes a dynamin-related protein 1 (Drp1)-filamin complex formation inhibitor comprising a compound of the present invention as an active ingredient. The dynamin-related protein 1 (Drp1)-filamin complex formation inhibitor, sometimes referred to herein as the "(Drp1)-filamin complex formation inhibitor of the present invention", is further described in the detailed description and specific embodiment 89 below.
[0017] In yet another aspect, the present invention includes compounds of the present invention that have advantageous properties compared to cilnidipine. In some aspects, the compounds have a similar ability to inhibit mitochondrial fission as cilnidipine, but have a reduced ability to block calcium channels compared to cilnidipine. In other aspects, the compounds have an enhanced ability to inhibit mitochondrial fission compared to cilnidipine, with or without a reduced ability to block calcium channels. Compounds with such advantageous properties are further described in the following detailed description and specific embodiments 52-64.
[0018] In a further aspect, the invention includes the compounds, pharmaceutical compositions, and (Drp1)-filamin complex formation inhibitors of the invention for use as prophylactic or therapeutic agents for, for example, diseases caused by Drp1 dysfunction, chronic heart failure, amyotrophic lateral sclerosis, inflammatory bowel disease, or diabetes, for example, type 1 and type 2 (type 1 / 2) diabetes. Methods of treating diseases caused by Drp1 dysfunction, chronic heart failure, amyotrophic lateral sclerosis, inflammatory bowel disease, and diabetes, for example, type 1 / 2 diabetes, using the compounds, pharmaceutical compositions, and (Drp1)-filamin complex formation inhibitors of the invention are also provided. Exemplary uses and methods of treatment are further described in the detailed description and specific embodiments 90-99 below.
[0019] The present invention further includes the following aspects. [1] A dynamin-related protein 1 (Drp1)-filamin complex formation inhibitor comprising, as an active ingredient, a compound represented by the following formula (1), or a pharmacologically acceptable salt or solvate thereof: [ka] [In formula (1), R 1 represents a phenyl group, a 2-pyridyl group, a 3-pyridyl group, or a 4-pyridyl group; R 2 represents a hydrogen atom or an amino group, R 3 represents a hydrogen atom or a nitro group, R 2 is a hydrogen atom, R 3 is a nitro group, and R 2 is an amino group, R 3 is a hydrogen atom]. [2] In formula (1), R 1 represents a phenyl group, a 2-pyridyl group, a 3-pyridyl group, or a 4-pyridyl group; R 2 represents a hydrogen atom, and R 3 represents a nitro group, or R 1 represents a 2-pyridyl group, a 3-pyridyl group, or a 4-pyridyl group; R 2 represents an amino group, and R 3 The Drp1-filamin complex formation inhibitor according to [1], wherein represents a hydrogen atom. [3] In formula (1), R 1 represents a phenyl group, a 2-pyridyl group, a 3-pyridyl group, or a 4-pyridyl group; R 2 represents an amino group, and R 3 The Drp1-filamin complex formation inhibitor according to [1], wherein represents a hydrogen atom. [4] The Drp1-filamin complex formation inhibitor according to any of [1] to [3], which is a preventive or therapeutic drug for a disease caused by Drp1 dysfunction. [5] The Drp1-filamin complex formation inhibitor according to [4], wherein the disease is chronic heart failure, amyotrophic lateral sclerosis, inflammatory bowel disease, or diabetes, for example, type 1 / 2 diabetes. [6] A pharmaceutical composition for inhibiting Drp1-filamin complex formation, comprising the Drp1-filamin complex formation inhibitor according to any one of [1] to [5] and a pharma- ceutical acceptable carrier. [7] A compound represented by the following formula (2), or a pharmacologically acceptable salt thereof, or a solvate thereof: [ka] [In formula (2), R 4 represents a phenyl group, a 2-pyridyl group, a 3-pyridyl group, or a 4-pyridyl group; R 5 represents an amino group, and R 6 represents a hydrogen atom]. Effect of the Invention
[0020] According to the present invention, it is possible to provide an inhibitor of Drp1-filamin complex formation. [Brief description of the drawings]
[0021] [Figure 1] 1(a) is a fluorescence microscope photograph of cells cultured under normoxia in Experimental Example 1. FIG. 1(b) is a fluorescence microscope photograph of cells cultured under hypoxia in Experimental Example 1. [Diagram 2]Figure 2(a) is a representative fluorescence micrograph of mitochondria. Figure 2(b) is an image showing the shape of mitochondria extracted by filtering from the photograph of Figure 2(a). Figure 2(c) is a graph showing the length of mitochondria in neonatal rat cardiomyocytes cultured under normoxia or hypoxia. [Diagram 3] FIG. 3 is a graph showing the results of measuring the proportion of cells having vesicular mitochondria in Experimental Example 2. [Figure 4] 4(a) is a diagram showing the experimental schedule of Experimental Example 3. FIG. 4(b) is a graph showing the measurement results of the survival rate in Experimental Example 3. [Diagram 5] 5(a) is a diagram showing the experimental schedule of Experimental Example 4. FIG. 5(b) is a graph showing the measurement results of the survival rate in Experimental Example 4. [Figure 6] FIG. 6 is a graph showing the change over time in blood glucose levels in each group of mice in Experimental Example 5. [Figure 7] FIG. 7 is a graph showing the analysis results of Experimental Example 6. [Figure 8] FIG. 8 is a graph showing the results of measuring the proportion of cells having tubular mitochondria in Experimental Example 8. [Figure 9] Fig. 9(a) is a fluorescence micrograph of cells in Experimental Example 9. Fig. 9(b) is a graph showing the measurement results of the average length of mitochondrial fragments as a result of image analysis of the fluorescence micrograph of Fig. 9(a). [Figure 10] FIG. 10 is a graph showing the results of measuring the ratio of p53-accumulating cells to α-actinin-positive cells in Experimental Example 10. [Figure 11] FIG. 11 is a graph showing the results of measuring the proportion of cells having vesicular mitochondria in Experimental Example 11. [Figure 12] FIG. 12 is a graph showing the increase in intracellular calcium ion concentration after potassium chloride stimulation in Experimental Example 12. [Figure 13] FIG. 13 is a graph showing the results of measuring the proportion of cells having vesicular mitochondria in Experimental Example 13. [Figure 14] FIG. 14 is a graph showing the results of measuring the proportion of cells having tubular mitochondria in Experimental Example 14. [Figure 15] FIG. 15 is a graph showing the increase in intracellular calcium ion concentration after potassium chloride stimulation in Experimental Example 15. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0022] (compound) In one aspect, the present invention provides a compound of formula (I): [ka] and its pharmacologically acceptable salts and solvates thereof, During the ceremony, The compound is [ka] If other than, R 1 is phenyl substituted with 1 to 3 substituents, each of which is independently NO2, NH2, OH, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 alkoxyalkyl, with the proviso that at least one substituent is NO2 or NH2; R 2 is H, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 alkoxyalkyl; R 3 is H, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 alkoxyalkyl; R 4 is C1-C6 alkyl or C1-C6 haloalkyl; R 5 is phenyl or pyridinyl, wherein the phenyl or pyridinyl is unsubstituted or substituted with 1 to 3 substituents, each of which is independently NO2, NH2, OH, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 alkoxyalkyl; (i) bond a is present and bonds b and c are absent, or (ii) bonds b and c are present and bond a is absent, A is NH when bond a is present, and N when bonds b and c are present; m is an integer from 1 to 4; n is an integer from 1 to 3.
[0023] As used herein, "C1-C n The term "alkyl" refers to a straight- or branched-chain unsubstituted alkyl having 1 to n carbon atoms in the chain. Examples of C1-C6 alkyl include methyl, ethyl, n-propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl (tBu), pentyl, isopentyl, tert-pentyl, hexyl, and isohexyl.
[0024] As used herein, "C1-C n The term "haloalkyl" refers to a straight- or branched-chain unsubstituted alkyl having 1 to n carbon atoms in the chain and in which one or more hydrogen atoms are replaced with a halogen. Examples of haloalkyl groups include trifluoromethyl (CF3), difluoromethyl (CF2H), monofluoromethyl (CH2F), pentafluoroethyl (CF2CF3), tetrafluoroethyl (CHFCF3), monofluoroethyl (CH2CH2F), and trifluoroethyl (CH2CF3).
[0025] As used herein, "C1-C n The term "alkoxyalkyl" refers to a straight- or branched-chain unsubstituted alkyl having 1 to n carbon atoms in the chain and having a terminal oxygen which attaches the group to the remainder of the molecule. Examples of C1-C6 alkoxy groups include methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, t-butoxy, pentoxy, and hexoxy.
[0026] As used herein, the term "phenyl" represents the following group: [ka] Substituents of a substituted phenyl group can be identified by their position on the phenyl ring, for example, the substituent may be at the 2-position, 3-position, or 4-position, the numbering of the positions referring to the positions as shown in the phenyl structure above.
[0027] As used herein, the term "pyridinyl" or "pyridyl" refers to a phenyl group in which one ring CH is replaced with a nitrogen atom. The pyridinyl group can be 2-pyridyl, 3-pyridyl, or 4-pyridyl. "2-pyridyl" refers to the following group: [ka] "3-pyridyl" refers to the group: [ka] "4-pyridyl" refers to the group: [ka]
[0028] The term "unsubstituted" with reference to a group means that the particular group has no substituents. The term "substituted" with reference to a group means that the particular group has one or more substituents. If a group is not explicitly described as substituted, such group is understood to be unsubstituted.
[0029] In some embodiments, the compound of formula (I) is a compound of formula (Ia). [ka]
[0030] In another embodiment, the compound of formula (I) is a compound of formula (Ib). [ka]
[0031] In some embodiments of the compounds of Formula (I) (including compounds of Formula (Ia) and Formula (Ib)), R 1 teeth, [ka] and In the formula, R 1a is NO2 or NH2, R 1b and R 1c are each independently H, NO, NH, OH, C-C alkyl, C-C haloalkyl, or C-C alkoxyalkyl. 1b and R 1c Both are H.
[0032] In some embodiments of the compounds of Formula (I) (including compounds of Formula (Ia) and Formula (Ib)), R 2 is H, C1-C3 alkyl, C1-C3 haloalkyl, or C1-C3 alkoxyalkyl. In some embodiments, R 2 is CH3.
[0033] In some embodiments of the compounds of Formula (I) (including compounds of Formula (Ia) and Formula (Ib)), R 3 is H, C1-C3 alkyl, C1-C3 haloalkyl, or C1-C3 alkoxyalkyl. In some embodiments, R 3 is CH3. In some embodiments, R 2 and R 3 Both are CH3.
[0034] In some embodiments of the compounds of Formula (I) (including compounds of Formula (Ia) and Formula (Ib)), R 4 is C1-C3 alkyl or C1-C3 haloalkyl. In some embodiments, R 4 is CH3.
[0035] In some embodiments of the compounds of Formula (I) (including compounds of Formula (Ia) and Formula (Ib)), R 5is phenyl that is unsubstituted or substituted with 1-3 substituents, each of which is independently NO, NH, OH, C-C alkyl, C-C haloalkyl, or C-C alkoxyalkyl. 5 is unsubstituted phenyl.
[0036] In some embodiments of the compounds of Formula (I) (including compounds of Formula (Ia) and Formula (Ib)), R 5 is pyridinyl that is unsubstituted or substituted with 1 to 3 substituents, each of which is independently NO, NH, OH, C-C alkyl, C-C haloalkyl, or C-C alkoxyalkyl. 5 is unsubstituted pyridinyl. In some embodiments, R 5 The pyridinyl group is 4-pyridyl (e.g., unsubstituted 4-pyridyl). In other embodiments, R 5 Pyridinyl is 3-pyridyl (e.g., unsubstituted 4-pyridyl). 5 Pyridinyl is 2-pyridyl (eg, unsubstituted 2-pyridyl).
[0037] In some embodiments of the compounds of Formula (I) (including compounds of Formula (Ia) and Formula (Ib)), m is 1. In other embodiments, m is 2. In other embodiments, m is 3. In still other embodiments, m is 4.
[0038] In some embodiments of the compounds of Formula (I) (including compounds of Formula (Ia) and Formula (Ib)), n is 1. In other embodiments, n is 2. In other embodiments, n is 3. In some embodiments, m is 2 and n is 1.
[0039] In some embodiments of the compounds of Formula (I) (including compounds of Formula (Ia) and Formula (Ib)), R 1 teeth, [ka] and In the formula, R 1a is NO2 or NH2, R 2 , R 3 , and R 4 is CH3 and R 5 is unsubstituted phenyl or unsubstituted pyridinyl (eg, unsubstituted 4-pyridyl, where m is 2 and n is 1).
[0040] In some embodiments, the compound of formula (I) is 3-(2-methoxyethyl) 5-[(2E)-3-phenyl-2-propen-1-yl] 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate. In other embodiments, the compound of formula (I) is 3-(2-methoxyethyl) 5-[(2E)-3-phenyl-2-propen-1-yl] 4-(3-aminophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate. In other embodiments, the compound of formula (I) is 3-(2-methoxyethyl) 5-[(2E)-3-phenyl-2-propen-1-yl] 2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylate. In another embodiment, the compound of formula (I) is 3-(2-methoxyethyl) 5-[(2E)-3-phenyl-2-propen-1-yl] 2,6-dimethyl-4-(4-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate. In another embodiment, the compound of formula (I) is 3-(2-methoxyethyl) 5-[(2E)-3-phenyl-2-propen-1-yl] 4-(4-aminophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate. In another embodiment, the compound of formula (I) is 3-(2-methoxyethyl) 5-[(2E)-3-(pyridin-4-yl)-2-propen-1-yl] 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate. In another embodiment, the compound of formula (I) is 3-(2-methoxyethyl) 5-[(2E)-3-(pyridin-4-yl)-2-propen-1-yl] 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate. In another embodiment, the compound of formula (I) is 3-(2-methoxyethyl) 5-[(2E)-3-(pyridin-4-yl)-2-propen-1-yl] 4-(3-aminophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate.In another embodiment, the compound of formula (I) is 3-(2-methoxyethyl) 5-[(2E)-3-(pyridin-4-yl)-2-propen-1-yl] 2,6-dimethyl-4-(4-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate.
[0041] In another aspect, the present invention provides a compound of formula (1): [ka] and its pharmacologically acceptable salts and solvates thereof, During the ceremony, R 1 represents a phenyl group, a 2-pyridyl group, a 3-pyridyl group, or a 4-pyridyl group; R 2 represents a hydrogen atom or an amino group, R 3 represents a hydrogen atom or a nitro group, R 2 is a hydrogen atom, R 3 is a nitro group, and R 2 is an amino group, R 3 is a hydrogen atom.
[0042] In some embodiments of the compound of Formula (1), R 1 represents a phenyl group, a 2-pyridyl group, a 3-pyridyl group, or a 4-pyridyl group; R 2 represents a hydrogen atom, and R 3 represents a nitro group, or R 1 represents a 2-pyridyl group, a 3-pyridyl group, or a 4-pyridyl group; R 2 represents an amino group, and R 3 represents a hydrogen atom. In some embodiments, R 1 represents a phenyl group, a 2-pyridyl group, a 3-pyridyl group, or a 4-pyridyl group; R 2 represents a hydrogen atom, and R 3 represents a nitro group. In another embodiment, R 1 represents a 2-pyridyl group, a 3-pyridyl group, or a 4-pyridyl group; R 2 represents an amino group, and R 3 represents a hydrogen atom. In another embodiment, R 1represents a phenyl group, a 2-pyridyl group, a 3-pyridyl group, or a 4-pyridyl group; R 2 represents an amino group, and R 3 represents a hydrogen atom.
[0043] In another aspect, the present invention provides a compound represented by the following formula (2) or a pharmacologically acceptable salt or solvate thereof: [ka] [In formula (2), R 4 represents a phenyl group, a 2-pyridyl group, a 3-pyridyl group, or a 4-pyridyl group; R 5 represents an amino group, and R 6 represents a hydrogen atom].
[0044] The compound represented by the above formula (2) is a novel compound. Specific examples of the compound represented by the above formula (2) include a compound represented by the following chemical formula (5) (hereinafter referred to as "NS4-700") and a compound represented by the following chemical formula (6) (hereinafter referred to as "NS4-238").
[0045] [ka]
[0046] [ka]
[0047] NS4-700 exhibits a higher inhibitory effect on mitochondrial fission than NS4-238, but does not block calcium channels. NS4-238 exhibits approximately three times stronger inhibitory effect on mitochondrial fission than cilnidipine, and blocks calcium channels to the same extent as cilnidipine.
[0048] In another aspect, the present invention provides a compound of formula (A): [ka] and its pharmacologically acceptable salts and solvates thereof, During the ceremony, R is NO2 or NH2, R is in the 2-, 3-, or 4-position of the phenyl ring, and the compound is [ka] Otherwise, X is CH or N.
[0049] In another aspect, the present invention provides a compound of formula (B): [ka] and its pharmacologically acceptable salts and solvates thereof, During the ceremony, R is NO2 or NH2, R is in the 2-, 3-, or 4-position of the phenyl ring, and X represents CH or N.
[0050] (Drp1-filamin complex formation inhibitor) In one aspect, the present invention comprises a dynamin-related protein 1 (Drp1)-filamin complex formation inhibitor comprising as an active ingredient a compound of formula (I) or a pharmacologically acceptable salt or solvate thereof, a compound of formula (1) or a pharmacologically acceptable salt or solvate thereof, a compound of formula (2) or a pharmacologically acceptable salt or solvate thereof, a compound of formula (A) or a pharmacologically acceptable salt or solvate thereof, or a compound of formula (B) or a pharmacologically acceptable salt or solvate thereof.
[0051] In one embodiment, the present invention provides a dynamin-related protein 1 (Drp1)-filamin complex formation inhibitor comprising a compound represented by the following formula (1) or a pharmacologically acceptable salt or solvate thereof as an active ingredient:
[0052] [ka] [In formula (1), R1 represents a phenyl group, a 2-pyridyl group, a 3-pyridyl group, or a 4-pyridyl group; R 2 represents a hydrogen atom or an amino group, R 3 represents a hydrogen atom or a nitro group, R 2 is a hydrogen atom, R 3 is a nitro group, and R 2 is an amino group, R 3 is a hydrogen atom].
[0053] The compound represented by the above formula (1) is a derivative of cilnidipine represented by the above chemical formula (A1). As described later in the Examples, the present inventors have revealed that the compound represented by formula (1) can inhibit the formation of the Drp1-filamin complex. Inhibiting the formation of the Drp1-filamin complex can suppress mitochondrial fission.
[0054] The Drp1-filamin complex formation inhibitor of this embodiment may also be understood as a compound represented by the above formula (1), or a pharmacologically acceptable salt thereof, or a solvate thereof.
[0055] Human Drp1 proteins have been assigned NCBI accession numbers NP_036193.2, NP_036192.2, NP_001265395.1, etc. Mouse Drp1 proteins have been assigned NCBI accession numbers NP_001021118.1, NP_001263269.1, NP_001263270.1, etc.
[0056] Filamins are exemplified by filamin A, filamin B, filamin C, etc. Human filamin A proteins have been assigned NCBI accession numbers NP_001104026.1, NP_001447.2, etc. Mouse filamin A proteins have been assigned NCBI accession numbers NP_001277350.1, NP_034357.2, etc.
[0057] Human filamin B proteins have been assigned NCBI accession numbers NP_001157789.1, NP_001157790.1, NP_001157791.1, etc. Mouse filamin B proteins have been assigned NCBI accession numbers NP_001074896.1, NP_598841.1, etc.
[0058] Human filamin C proteins have been assigned NCBI accession numbers NP_001120959.1, NP_001449.3, etc. Mouse filamin C proteins have been assigned NCBI accession numbers NP_001074654.1, NP_001298003.1, etc.
[0059] In this patent specification, the expression "... contains ... as an active ingredient" means "... contains ... as a main active ingredient." The Drp1-filamin complex formation inhibitor of the present invention includes a compound represented by (a) formula (I) or a pharmacologically acceptable salt or solvate thereof, (b) formula (1) or a pharmacologically acceptable salt or solvate thereof, (c) formula (2) or a pharmacologically acceptable salt or solvate thereof, (d) formula (A) or a pharmacologically acceptable salt or solvate thereof, or (e) formula (E) or a pharmacologically acceptable salt or solvate thereof, but the content is not particularly limited. In some embodiments, the Drp1-filamin complex formation inhibitor of the present invention includes a compound represented by formula (1) or a pharmacologically acceptable salt or solvate thereof.
[0060] (Pharmacologically acceptable salts and solvates) The compound represented by formula (I), formula (1), formula (2), formula (A), or formula (B) may be a free species, a pharmacologically acceptable salt of the compound represented by formula (I), formula (1), formula (2), formula (A), or formula (B), a solvate of the compound represented by formula (I), formula (1), formula (2), formula (A), or formula (B), or a solvate of a pharmacologically acceptable salt of the compound represented by formula (I), formula (1), formula (2), formula (A), or formula (B). In some embodiments, the compound is in the form of a solvate, more specifically a hydrate. In other embodiments, the compound is not in the form of a solvate.
[0061] Pharmaceutically acceptable salts are exemplified by hydrochlorate, sulfate, hydrobromate, hydroiodide, phosphate, nitrate, benzoate, methanesulfonate, 2-hydroxyethanesulfonate, p-toluenesulfonate, acetate, propanoate, oxalate, malonate, succinate, glutarate, adipate, tartrate, maleate, fumarate, malate, or mandelate.
[0062] The solvate is not particularly limited, so long as it is a pharma- ceutically acceptable solvate, and is exemplified by hydrates and organic solvates, in some embodiments, the solvate is a hydrate.
[0063] In certain embodiments, the present invention provides compounds of the present invention, such as the compounds described above, that have advantageous properties compared to cilnidipine.In some embodiments, the compounds have the same ability as cilnidipine to inhibit mitochondrial fission, but have reduced ability to block calcium channels compared to cilnidipine.For example, the compounds of the present invention can have at least 50% of the mitochondrial fission inhibitory activity of cilnidipine, at least 75% of the mitochondrial fission inhibitory activity of cilnidipine, at least 90% of the mitochondrial fission inhibitory activity of cilnidipine, or at least equal to the mitochondrial fission inhibitory activity of cilnidipine.The mitochondrial fission inhibitory activity can be determined by, for example, the evaluation system of Experimental Example 1, as described herein.
[0064] In other embodiments, the compound of the present invention has enhanced ability to inhibit mitochondrial fission compared to cilnidipine, with or without decreased ability to block calcium channel.For example, the compound of the present invention can have (a) at least 100%, at least 125% or at least 150% (and optionally up to 200%, up to 300% or more than up to 300%) of the mitochondrial fission inhibitory activity of cilnidipine, and optionally (b) calcium channel blocking activity of 75% or less, 50% or less, 25% or less, or 10% or less of the calcium channel blocking activity of cilnidipine.The mitochondrial fission inhibitory activity can be determined as described herein, for example, by the evaluation system of Experimental Example 1, and the calcium channel blocking activity can be determined as described herein, for example, by the evaluation system of Experimental Example 12.
[0065] Exemplary Drp1-Filamin Complex Formation Inhibitors Embodiments <First embodiment> Regarding the Drp1-filamin complex formation inhibitor of the first embodiment, the compound represented by formula (1) is R 1 represents a phenyl group, a 2-pyridyl group, a 3-pyridyl group, or a 4-pyridyl group; R 2 represents a hydrogen atom, and R 3Alternatively, with respect to the Drp1-filamin complex formation inhibitor of the first embodiment, the compound represented by formula (1) may be such that R 1 represents a 2-pyridyl group, a 3-pyridyl group, or a 4-pyridyl group; R 2 represents an amino group, and R 3 represents a hydrogen atom.
[0066] As described later in the Examples, the present inventors have clarified that the cilnidipine derivative of the first embodiment has a Drp1-filamin complex formation inhibitor. The present inventors have also clarified that the cilnidipine derivative of the first embodiment does not act to block calcium channels, unlike cilnidipine, which blocks calcium channels. That is, the cilnidipine derivative of the first embodiment does not exhibit a hypotensive effect.
[0067] As described later in the Examples, the inventors have demonstrated that cilnidipine exhibits therapeutic effects against intractable diseases such as amyotrophic lateral sclerosis (ALS), inflammatory bowel disease, and diabetes, e.g., type 1 / 2 diabetes.
[0068] However, administration of cilnidipine is difficult for non-hypertensive patients due to its hypotensive effect. In contrast, the cilnidipine derivative of the first embodiment, which does not have the hypotensive effect, can be administered to non-hypertensive patients.
[0069] Specific examples of the cilnidipine derivative of the first embodiment include a compound represented by the following chemical formula (3) (hereinafter referred to as "NS4-019"), a compound represented by the following chemical formula (4) (hereinafter referred to as "NS4-043"), and a compound represented by the following chemical formula (5) (hereinafter referred to as "NS4-700").
[0070] [ka]
[0071] [ka]
[0072] [ka]
[0073] As described later in the Examples, NS4-019 and NS4-043 exhibit inhibitory potency against mitochondrial division to a degree equivalent to that of cilnidipine, while NS4-700 exhibits inhibitory potency against mitochondrial division to a high degree comparable to that of NS4-238 described later.
[0074] <Second embodiment> Regarding the Drp1-filamin complex formation inhibitor of the second embodiment, the compound represented by formula (1) is R 1 represents a phenyl group, a 2-pyridyl group, a 3-pyridyl group, or a 4-pyridyl group; R 2 represents an amino group, and R 3 represents a hydrogen atom.
[0075] As described later in the Examples, the present inventors have demonstrated that the cilnidipine derivative of the second embodiment exhibits approximately three times stronger inhibitory activity against mitochondrial division than cilnidipine.
[0076] Specific examples of the cilnidipine derivative of the second embodiment include a compound represented by the following chemical formula (5) (hereinafter referred to as "NS4-700") and a compound represented by the following chemical formula (6) (hereinafter referred to as "NS4-238").
[0077] [ka]
[0078] [ka]
[0079] As described later in the Examples, NS4-700 exhibits a higher ability to inhibit mitochondrial fission than NS4-238, but does not block calcium channels. Again, as described later in the Examples, NS4-238 exhibits an ability to inhibit mitochondrial fission approximately three times stronger than cilnidipine, and blocks calcium channels to the same extent as cilnidipine.
[0080] (Preventive or therapeutic drugs) In one embodiment, the present invention provides a preventive or therapeutic agent for a disease caused by Drp1 dysfunction, comprising any of the aforementioned compounds and a Drp1-filamin complex formation inhibitor of the present invention as an active ingredient. Diseases caused by Drp1 dysfunction are exemplified by chronic heart failure, amyotrophic lateral sclerosis (ALS), inflammatory bowel disease, and diabetes, e.g., type 1 / 2 diabetes.
[0081] With regard to the prophylactic or therapeutic agents of this embodiment, the aforementioned compounds or Drp1-filamin complex formation inhibitors are preferably mixed with a pharma- ceutically acceptable carrier and formulated as a pharmaceutical composition. The pharmaceutical composition may have an oral or parenteral dosage form. Oral dosage forms are exemplified by tablets, pills, capsules, elixirs, and microcapsules. Parenteral dosage forms are exemplified by injections, inhalants, suppositories, and patches.
[0082] Pharmaceutically acceptable carriers are exemplified by purified water, bases such as titanium oxide, carnauba wax, synthetic squalane, crotamiton, and gelatin, binders such as ethyl cellulose, glycerin, and methacrylic acid copolymer S, excipients such as microcrystalline cellulose, croscarmellose sodium, magnesium stearate, and hypromellose, stabilizers such as gum arabic, magnesium aluminometasilicate, povidone, benzyl alcohol, sodium acetate, and magnesium stearate, plasticizers such as Macrogol 400 and Macrogol 6000, and solubilizers such as benzyl benzoate and benzyl alcohol.
[0083] The pharmaceutical composition may further comprise additives, exemplified by sweeteners such as sucrose, lactose, and saccharin, flavoring agents such as peppermint and l-menthol, and preservatives such as benzoic acid, salicylic acid, thimerosal, and phenol.
[0084] The pharmaceutical compositions can be formulated by suitably combining the above-mentioned carriers and additives and mixing them according to any of the unit dosage forms required by generally accepted pharmaceutical practice.
[0085] The pharmaceutical composition may be characterized by the purity of the compound of the present invention. For example, in certain aspects, the pharmaceutical composition does not contain any active pharmaceutical ingredient other than the compound of the present invention, and in certain embodiments, the pharmaceutical composition is substantially free of cilnidipine. As used herein, the term "substantially free of cilnidipine" refers to a detectable amount of cilnidipine, a therapeutically effective amount of cilnidipine, and / or any amount of cilnidipine. In a further aspect, the compound of the present invention in the pharmaceutical composition is at least 90% pure (e.g., at least 95% pure, 98% pure, or 99% pure). The purity percentage refers to the purity of the active pharmaceutical ingredient in the pharmaceutical composition excluding carriers, e.g., excipients.
[0086] A pharmaceutical composition comprising a compound of the invention is preferably in a dosage form comprising: (a) at least 1 mg of a compound of the invention, at least 2 mg of a compound of the invention, at least 5 mg of a compound of the invention, at least 10 mg of a compound of the invention, and / or (b) up to 20 mg of a compound of the invention, up to 25 mg of a compound of the invention, or up to 50 mg of a compound of the invention.
[0087] Administration to a patient can typically be performed by any method known to those skilled in the art, such as intraarterial injection, intravenous injection, subcutaneous injection, and intranasal, transbronchial, intramuscular, transdermal, or oral methods. The dosage may vary depending on the patient's body weight, age, and symptoms, as well as the administration method. The appropriate dosage can be appropriately selected by those skilled in the art.
[0088] The dosage of Drp1-filamin complex formation inhibitors may vary depending on the type of Drp1-filamin complex formation inhibitor and the patient's symptoms, but the oral dosage for adults (assuming a body weight of 60 kg) is usually thought to be about 1-30 mg per day, administered once or several times a day.
[0089] Although parenteral dosages may vary depending on the type of Drp1-filamin complex formation inhibitor, the patient's symptoms, the target organ, the method of administration, etc., systemic administration to an adult (assuming a body weight of 60 kg) is usually considered to be about 0.1-10 mg per day, administered once or several times a day, whereas local administration to an adult (assuming a body weight of 60 kg) is usually considered to be about 0.1-10 mg per day, administered once or several times a day.
[0090] (Other embodiments) In one embodiment, the invention provides a method for preventing or treating a disease caused by impaired Drp1 function comprising administering to a patient in need of treatment an effective dose of a Drp1-filamin complex formation inhibitor.
[0091] In one embodiment, the invention provides a Drp1-filamin complex formation inhibitor for the prevention or treatment of a disease caused by impaired Drp1 function.
[0092] In one embodiment, the invention provides the use of a Drp1-filamin complex formation inhibitor for the manufacture of a drug for the prevention or treatment of a disease caused by impaired Drp1 function.
[0093] In all of these embodiments, the Drp1-filamin complex formation inhibitor is the same as any of those previously described, and the disease caused by Drp1 dysfunction is the same as those previously described.
[0094] (Synthetic scheme) The following synthetic schemes can be used to prepare compounds of the invention. In Schemes A-D, R 1a , R 1b , R 1c , R2 , R 3 , R 4 , and R 5 is as defined herein for compounds of formula (I).
[0095] [ka]
[0096] In Scheme A, R 1a , R 1b , R 1c , R 2 , R 3 , R 4 , and R 5 One equivalent of compound A, one equivalent of compound B, and one equivalent of compound C, each having a protecting group at R, are combined in 2-propanol and stirred at about 70° C. for a period of time (e.g., 24-72 hours) to provide compound D. Suitable protecting groups are known and readily selected by one of skill in the art (see, e.g., Wuts and Greene, 2007, Greene's Protective Groups in Organic Synthesis, Fourth Edition, John Wiley & Sons, Inc.; Kocienski, 2005, Protecting Groups, Third Edition, Thieme). For example, the amine group can be protected with a tert-butyloxycarbonyl (Boc) protecting group. Compound D can be purified, for example, by flash column chromatography on silica gel. R 1a , R 1b , R 1c , R 2 , R 3 , R 4 , and R 5 The protecting groups, if present, can be removed by standard means before or after the purification step. For example, Boc-protected amines can be deprotected by acid hydrolysis (e.g., treating the protected amine in dichloromethane with trifluoroacetic acid).
[0097] [ka]
[0098] In Scheme B, R is added as necessary. 1a , R 1b , R 1c , R 2 , R 3 , R 4 , and R 5 One equivalent of compound E, one equivalent of compound F, and one equivalent of compound C, each having a protecting group at R, can be combined in 2-propanol and stirred at about 70° C. for a period of time (e.g., 24-72 hours) to provide compound D. Compound D can be purified, for example, by flash column chromatography on silica gel. 1a , R 1b , R 1c , R 2 , R 3 , R 4 , and R 5 The protecting groups in, if present, may be removed by standard means before or after the purification step.
[0099] [ka]
[0100] In Scheme C, R is added as necessary. 1b , R 1c , R 2 , R 3 , R 4 , and R 5 Compound G bearing a protecting group at R (e.g., produced according to Scheme A or Scheme B) can be combined with excess iron powder (e.g., 55 equivalents per equivalent of compound G) in glacial acetic acid and stirred at about 100° C. (e.g., for 15 minutes). The reaction mixture can then be diluted with ethyl acetate and filtered through a pad of Celite. The filtrate can be washed sequentially with a saturated aqueous solution of sodium bicarbonate and brine, dried over magnesium sulfate, and concentrated in vacuo. The residue can then be purified, for example, by flash column chromatography on silica gel, to provide compound H. 1b , R1c , R 2 , R 3 , R 4 , and R 5 The protecting groups in, if present, can be removed by standard means before or after the purification step.
[0101] [ka]
[0102] In Scheme D, R is used as needed. 1a , R 1b , R 1c , R 2 , R 3 , R 4 , and R 5 A stirred solution of compound D (e.g., made according to Scheme A or Scheme B) in dichloromethane having a protecting group at R can be combined with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone DDQ. After stirring at ambient temperature for, e.g., 2 hours, the reaction mixture can be purified, e.g., by flash column chromatography on silica gel, to provide compound I. 1a , R 1b , R 1c , R 2 , R 3 , R 4 , and R 5 The protecting groups in, if present, can be removed by standard means before or after the purification step. EXAMPLES
[0103] The present invention will be further described below with reference to examples. However, the present invention is not limited to the following examples.
[0104] (Experimental Example 1) <Establishment of a system for evaluating the degree of mitochondrial division> A system was developed to quantitatively evaluate the degree of intracellular mitochondrial fission. More specifically, cardiomyocytes obtained from neonatal rats were cultured for 16 hours under normoxia (20%) or hypoxia (1%). The cells were then stained with a fluorescent dye (MitoTracker Green FM, Thermo Fisher Scientific Inc.) that selectively stains mitochondria. The cells were observed under a fluorescent microscope, and the mitochondrial shape was quantified by image analysis.
[0105] Figures 1(a) and 1(b) are representative fluorescence micrographs of mitochondria: Figure 1(a) is a fluorescence micrograph of cells cultured under normoxia, and Figure 1(b) is a fluorescence micrograph of cells cultured under hypoxia.
[0106] Figures 2(a) and 2(b) are photographs and images illustrating a method for quantifying mitochondrial shape by image analysis. Figure 2(a) is a representative fluorescent micrograph of mitochondria. Figure 2(b) is an image showing mitochondrial shape extracted by filtering from the photograph of Figure 2(a). The image of Figure 2(b) was analyzed to quantify mitochondrial shape.
[0107] Figure 2(c) is a graph showing the mitochondrial length of neonatal rat cardiomyocytes cultured under normoxia or hypoxia. In Figure 2(c), "normoxia" represents the results obtained from culture under normal oxygen concentration, and "hypoxia" represents the results obtained from culture under hypoxia. As shown in Figure 2(c), mitochondria smaller than 3.5 μm were classified as vesicular, mitochondria larger than 4.2 μm were classified as tubular, and mitochondria with sizes between 3.6 μm and 4.2 μm were classified as intermediate.
[0108] The results showed that neonatal rat cardiomyocytes cultured under normoxia produced a high percentage of tubular mitochondria, whereas neonatal rat cardiomyocytes cultured under hypoxia (1%) induced mitochondrial fission and produced a high percentage of vesicular mitochondria. It was also confirmed that the method of this experimental example can quantitatively evaluate mitochondrial morphology.
[0109] (Experimental Example 2) <Screening of existing drugs> Compounds capable of suppressing mitochondrial fission in a hypoxic environment were screened from existing drugs using the evaluation system constructed in Experimental Example 1. The existing drugs examined here include cilnidipine represented by the following chemical formula (A1), amlodipine represented by the following chemical formula (A2), nifedipine represented by the following chemical formula (A3), nicardipine represented by the following chemical formula (A4), nisoldipine represented by the following chemical formula (A5), and nitrendipine represented by the following chemical formula (A6).
[0110] [ka]
[0111] [ka]
[0112] [ka]
[0113] [ka]
[0114] [ka]
[0115] [ka]
[0116] Each of the aforementioned compounds was added to the culture medium of neonatal rat cardiomyocytes so that the final concentration was adjusted to 1 μM, and the cells were incubated for 1 hour and further cultured in a hypoxic environment for 16 hours. Next, the cells were stained using MitoTracker Green FM (Thermo Fischer Scientific Inc.) in the same manner as described in Experimental Example 1, observed under a fluorescent microscope, and the mitochondrial shape was quantified. For comparison, a group was prepared in which dimethyl sulfoxide (DMSO) was added instead of the drug.
[0117] 3 is a graph showing the results of measuring the percentage of cells having vesicular mitochondria. The results demonstrated that cilnidipine can significantly inhibit mitochondrial fission under hypoxic stimulation.
[0118] (Experimental Example 3) <Improvement of amyotrophic lateral sclerosis by administration of cilnidipine> The effect of cilnidipine on intractable diseases was investigated. In this experiment, cilnidipine was administered to a mouse model of amyotrophic lateral sclerosis (ALS) and the survival rate was examined. The ALS model mouse used was the SOD1-G93A mouse.
[0119] Figure 4(a) shows the experimental schedule. An osmotic pump containing 5,000 μg / kg of cilnidipine was implanted into the abdominal cavity of each model mouse after the onset of ALS, and the drug was administered continuously for 28 days, and the survival rate was measured.
[0120] FIG. 4(b) is a graph showing the results of measuring the survival rate. In FIG. 4(b), "SOD1-G93A" represents the results obtained from the ALS model mice, and "SOD1-G93A+CIL" represents the results obtained from the ALS model mice after administration of cilnidipine. The results revealed that the mice in the cilnidipine-administered group showed a significant increase in survival time compared to the non-cilnidipine-administered group. The results suggest the therapeutic effect of cilnidipine on ALS.
[0121] (Experimental Example 4) <Improvement of inflammatory bowel disease by administration of cilnidipine> The effect of cilnidipine on intractable diseases was investigated. In this experimental example, cilnidipine was administered to model mice with inflammatory bowel disease, and the survival rate was examined. The model mice used were mice in which inflammatory bowel disease was induced by administration of dextran sulfate (DSS).
[0122] Figure 5(a) shows the experimental schedule. Three days before the start of DSS administration, an osmotic pump containing 25,000 μg / kg of cilnidipine was implanted into the abdominal cavity of each mouse, and the drug was administered continuously for 17 days, after which the survival rate was measured.
[0123] From the first day of cilnidipine administration (day 0), mice were given tap water containing 3% DSS as drinking water for 7 days. From days 7 to 14 after the start of cilnidipine administration, drinking water was changed back to normal tap water. In addition, a control group was prepared in which mice were given only the solvent instead of cilnidipine.
[0124] Fig. 5(b) is a graph showing the results of measuring the survival rate. In Fig. 5(b), "3% DSS Veh" represents the results obtained from the inflammatory bowel disease model mice administered with only the solvent, and "3% DSS CIL" represents the results obtained from the inflammatory bowel disease model mice administered with cilnidipine.
[0125] The results showed that mice administered cilnidipine showed a significant increase in survival rate compared to mice not administered cilnidipine, suggesting the preventive or therapeutic effect of cilnidipine on inflammatory bowel disease.
[0126] (Experimental Example 5) <Initial improvement of diabetes with cilnidipine administration> The effect of cilnidipine on intractable diseases was investigated. In this experimental example, cilnidipine was administered to model mice with type 1 / 2 diabetes, and blood glucose levels were measured over time. The model mice with type 1 / 2 diabetes were intraperitoneally administered 200 mg / kg of streptozotocin (STZ) on the 42nd day after birth. For comparison, mice that had not been administered streptozotocin were also prepared.
[0127] The blood glucose levels of the mice in each group were monitored over time after the start of the experiment. On the 14th day after the start of the experiment, osmotic pumps containing 5,000 μg / kg of cilnidipine or vehicle alone were implanted in each mouse in each group for long-term administration.
[0128] Figure 6 is a graph showing the time course of blood glucose levels in each group of mice. In Figure 6, "STZ Veh" represents the results obtained from model mice with type 1 / 2 diabetes administered with only the solvent, "STZ CIL" represents the results obtained from model mice with type 1 / 2 diabetes administered with cilnidipine, "sham Veh" represents the results obtained from control mice administered with only the solvent, and "sham CIL" represents the results obtained from control mice administered with cilnidipine.
[0129] The results showed that the type 1 / 2 diabetes model mice showed blood glucose levels closer to normal levels after administration of cilnidipine, suggesting the therapeutic effect of cilnidipine on type 1 / 2 diabetes.
[0130] (Experimental Example 6) <Secondary improvement in type 2 diabetes with cilnidipine administration> The effect of cilnidipine on intractable diseases was investigated. The results shown in this experimental example were obtained from a retrospective analysis of patients at Kyushu University Hospital. In this experimental example, the proportion of HbA1c in the blood of hypertensive patients and hyperglycemic patients administered amlodipine, and hypertensive patients and hyperglycemic patients administered cilnidipine was evaluated.
[0131] Figure 7 is a graph showing the analysis results. In Figure 7, "amlodipine" represents the analysis results of patients administered amlodipine, and "cilnidipine" represents the analysis results of patients administered cilnidipine. The numbers in the graph represent the number of patients.
[0132] From the results, it was revealed that patients administered cilnidipine showed a significant decrease in HbA1c compared to patients administered amlodipine. The results suggest the therapeutic effect of cilnidipine on type 2 diabetes.
[0133] (Experimental Example 7) <Synthesis of Cilnidipine Derivatives> Cilnidipine derivatives were synthesized.
[0134] <<Synthesis of NS4-019>> The compound represented by the following chemical formula (3) (hereinafter referred to as "NS4-019") was synthesized according to the following Scheme I.
[0135]
Chemical formula
[0136]
Chemical formula
[0137] More specifically, 2-methoxyethyl acetoacetate (164 mg, 1.02 mmol), 2-nitrobenzaldehyde (153 mg, 1.01 mmol), and cinnamyl 3-aminocrotonate (220 mg, 1.01 mmol) were dissolved in 2-propanol (10 mL), and the mixture was stirred at 70 °C for 72 hours. Next, the solvent was evaporated, and the residue was purified by silica gel column chromatography (hexane:ethyl acetate gradient from 2:1 to 3:2) to obtain NS4-019 (283 mg, 57% yield) as a yellow viscous oil.
[0138] 1 H NMR (500 MHz, CDCl3): 7.70 (dd, J = 8.0, 1.0 Hz, 1H), 7.53 (dd, J = 8.0, 1.0 Hz, 1H), 7.45 (td, J = 8.0, 1.0 Hz, 1H), 7.34 - 7.20 (m, 6H), 6.45 (d, J = 16.0 Hz, 1H), 6.19 (dt, J = 16.0, 6.5 Hz, 1H), 5.89 (s, 1H), 5.75 (s, 1H), 4.69 (ddd, J = 13.0, 6.5, 1.0 Hz, 1H), 4.63 (ddd, J = 13.0, 6.5, 1.0 Hz, 1H), 4.27 - 4.21 (m, 1H), 4.08 - 4.02 (m, 1H), 3.59 - 3.47 (m, 2H), 3.26 (s, 3H), 2.33 (s, 3H), 2.32 (s, 3H). ESI-MS m / z: 515.2 [M+Na] + .
[0139] <<Synthesis of NS4-021>> The compound represented by the following chemical formula (7) (hereinafter referred to as "NS4-021") was synthesized according to the following Scheme II.
[0140]
Chemical formula
[0141]
Chemical formula
[0142] More specifically, silnidipine (50.8 mg, 0.103 mmol) was dissolved in dichloromethane (3 mL), and 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (31.5 mg, 0.139 mmol) was added. The mixture was stirred at room temperature for 2 hours, and the reaction mixture was purified by silica gel column chromatography (chloroform:ethyl acetate = 8:1) to obtain NS4-021 (44.8 mg, yield 89%) as a colorless viscous oil.
[0143] 1 H NMR (500 MHz, CDCl3): δ 8.16 (t, J = 2.0 Hz, 1H), 8.00 (ddd, J = 8.0, 2.5, 1.0 Hz, 1H), 7.57 (dt, J = 8.0, 1.0 Hz, 1H), 7.41 (t, J = 8.0 Hz, 1H), 7.36 - 7.29 (m, 3H), 7.26 - 7.23 (m, 2H), 6.45 (d, J = 16.0 Hz, 1H), 5.86 (dt, J = 16.0, 7.0 Hz, 1H), 4.63 (dd, J = 7.0, 1.0 Hz, 2H), 4.14 - 4.09 (m, 2H), 3.32 (t, J = 5.0 Hz, 2H), 3.21 (s, 3H), 2.65 (s, 3H), 2.64 (s, 3H). ESI-MS m / z: 513.2 [M+Na] + .
[0144] <<Synthesis of NS4-043>> The compound represented by the following chemical formula (4) (hereinafter referred to as "NS4-043") was synthesized according to the following Scheme III.
[0145]
Chemical formula
[0146]
Chemical formula
[0147] More specifically, (E)-3-(4-pyridyl)allyl acetoacetate (220 mg, 1.00 mmol), 2-nitrobenzaldehyde (153 mg, 1.01 mmol) and 2-methoxyethyl 3-aminocrotonate (162 mg, 1.02 mmol) were dissolved in 2-propanol (5 mL), and the mixture was stirred at 70 °C for 36 hours. The solvent was evaporated, and the residue was purified by silica gel column chromatography (hexane:ethyl acetate gradient from 1:1 to 1:6) to obtain NS4-043 (128 mg, 26% yield) as a yellow solid.
[0148] 1 HNMR(500MHz,CDCl3):8.52(d,J=6.5Hz,2H),7.71(dd,J=8.0,1.5Hz,1H),7.54(dd,J=8.0,1.5Hz,1H),7.47(td,J=8.0,1.5Hz,1H),7.26-7.23(m,1H),7.18(d,J=6.5Hz,2H),6.41(dt,J=16.0,6.0Hz,1H),6.33(d,J=16.0Hz,1H),5.91(s,1H),5.67(s,1H),4.72(ddd,J=13.5,6.0,1.0Hz,1H),4.65(ddd,J=13.5,6.0,1.0Hz,1H),4.27-4.21(m,1H),4.09-4.04(m,1H),3.58-3.48(m,2H),3.26(s,3H),2.35(s,3H),2.34(s,3H).ESI-MS m / z:494.2[M+H] + .
[0149] <<Synthesis of NS4-238>> The compound represented by the following chemical formula (6) (hereinafter referred to as "NS4-238") was synthesized according to the following Scheme IV.
[0150]
Chemical formula
[0151]
Chemical formula
[0152] More specifically, silnidipine (67.9 mg, 0.138 mmol) was dissolved in acetic acid (2 mL), and iron powder (425 mg, 7.60 mmol) was added. The mixture was stirred at 100 °C for 15 minutes, the reaction mixture was diluted with ethyl acetate, and then filtered through celite to separate the solid components. The filtrate was washed with saturated aqueous sodium bicarbonate and saturated brine, the organic layer was dried over sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform:ethyl acetate = 3:2) to obtain NS4-238 (50.0 mg, yield 78%) as a pale yellow viscous oil.
[0153] 1 HNMR (500 MHz, CDCl3): 7.35 (d, J = 7.0 Hz, 2H), 7.30 (t, J = 7.5 Hz, 2H), 7.24 (t, J = 7.0 Hz, 1H), 6.99 (t, J = 7.5 Hz, 1H), 6.71 (d, J = 7.5 Hz, 1H), 6.66 (t, J = 2.0 Hz, 1H), 6.53 (d, J = 16.0 Hz, 1H), 6.46 (ddd, J = 8.0, 2.5, 1.0 Hz, 1H), 6.24 (dt, J = 16.0, 6.0 Hz, 1H), 5.62 (s, 1H), 5.01 (s, 1H), 4.77 (ddd, J = 13.5, 6.0, 1.5 Hz, 1H), 4.67 (ddd, J = 13.5, 6.0, 1.5 Hz, 1H), 4.26 - 4.14 (m, 2H), 3.57 - 3.54 (m, 2H), 3.32 (s, 3H), 2.35 (s, 3H), 2.32 (s, 3H). ESI-MS m / z: 463.2 [M + H] + .
[0154] <<Synthesis of NS4-700>> The compound represented by the following chemical formula (5) (hereinafter referred to as "NS4-700") was synthesized according to the following Scheme V.
[0155]
Chemical formula
[0156] [ka]
[0157] More specifically, (E)-3-(4-pyridyl)allyl acetoacetate (42.3 mg, 0.193 mmol), 3-(Boc-amino)benzaldehyde (43.8 mg, 0.198 mmol) and 2-methoxyethyl 3-aminocrotonate (30.8 mg, 0.193 mmol) were dissolved in 2-propanol (1 mL) and the mixture was stirred at 70 °C for 24 h. The solvent was evaporated and the residue was purified by silica gel column chromatography (hexane:ethyl acetate graded from 1:2 to 1:3) to give intermediate Boc-NS4-700 (36.8 mg, 34% yield) as a colorless amorphous material. The intermediate (31.3 mg, 55.5 μmol) was dissolved in dichloromethane (2 mL) and trifluoroacetic acid (0.5 mL) was added dropwise. The mixture was stirred at room temperature for 20 min, and the reaction was neutralized with saturated aqueous sodium bicarbonate and extracted twice with dichloromethane. The resulting organic layers were combined, washed with saturated brine, dried over magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform:methanol graded from 100:1 to 25:1) to give NS4-700 (19.9 mg, 77% yield) as a colorless amorphous material.
[0158] 1HNMR(500MHz,CDCl3): δ 8.51 (d, J = 5.5 Hz, 2H), 7.18 (d, J = 5.5 Hz, 2H), 7.00 (t, J = 8.0 Hz, 1H), 6.73 (dt, J = 7.5, 1.0 Hz, 1H), 6.68 (t, J = 2.0 Hz, 1H), 6.47 (ddd, J = 8.0, 2.5, 1.0 Hz, 1H), 6.42 (dt, J = 16.0, 5.0 Hz, 1H), 6.31 (d, J = 16.0 Hz, 1H), 5.99 (s, 1H), 5.02 (s, 1H), 4.86 (ddd, J = 14.5, 5.0, 1.5 Hz, 1H), 4.66 (ddd, J = 14.5, 5.0, 1.5 Hz, 1H), 4.29 - 4.23 (m, 1H), 4.20 - 4.15 (m, 1H), 3.60 - 3.56 (m, 2H), 3.33 (s, 3H), 2.37 (s, 3H), 2.31 (s, 3H). ESI-MS m / z: 464.2 [M+H] + .
[0159] <<Synthesis of JYK-002>> The compound represented by the following chemical formula (8) (hereinafter referred to as "JYK-002") was prepared from 2-methoxyethyl 3-oxobutanoate, (E)-3-phenyl-2-propen-1-yl 3-aminobut-2-enoate, and 4-nitrobenzaldehyde according to the procedure described for NS4-019.
[0160] [Chemical formula]
[0161] 1 H NMR(400MHz,CDCl3) δ: 8.02 (d, J = 8.0 Hz, 2H), 7.44 (d, J = 8.0 Hz, 2H), 7.29 - 7.21 (m, 5H), 6.47 (d, J = 16.0 Hz, 1H), 6.14 (dt, J = 16.0, 6.4 Hz, 1H), 5.64 (s, 1H), 5.13 (s, 1H), 4.73 - 4.59 (m, 2H), 4.21 - 4.07 (m, 2H), 3.54 - 3.43 (m, 2H), 3.27 (s, 3H), 2.35 (s, 3H), 2.32 (s, 3H). ESI-MS m / z: 493.2 [M+H]+ .
[0162] <<Synthesis of JYK-003>> The compound represented by the following chemical formula (9) (hereinafter referred to as "JYK-003") was prepared from 3-(2-methoxyethyl) 5-[(2E)-3-phenyl-2-propen-1-yl] 2,6-dimethyl-4-(4-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate according to the procedure described for NS4-238.
[0163]
Chemical formula
[0164] 1 H NMR (500 MHz, CDCl3) δ: 7.36 - 7.28 (m, 4H), 7.24 (tt, J = 7.0, 1.5 Hz, 1H), 7.09 (d, J = 8.5 Hz, 2H), 6.53 (d, J = 8.5 Hz, 2H), 6.50 (d, J = 16.0 Hz, 1H), 6.22 (dt, J = 16.0, 6.0 Hz, 1H), 5.56 (s, 1H), 4.95 (s, 1H), 4.76 (ddd, J = 13.5, 6.0, 1.5 Hz, 1H), 4.66 (ddd, J = 13.5, 6.0, 1.5 Hz, 1H), 4.24 - 4.13 (m, 2H), 3.57 - 3.53 (m, 2H), 3.32 (s, 3H), 2.34 (s, 3H), 2.32 (s, 3H). ESI-MS m / z: 463.2 [M + H] + .
[0165] <<Synthesis of JYK-001>> The compound represented by the following chemical formula (10) (hereinafter referred to as "JYK-001") was prepared from 2-methoxyethyl 3-aminobut-2-enoate, (E)-3-(pyridin-4-yl)-2-propen-1-yl 3-oxobutanoate, and 3-nitrobenzaldehyde according to the procedure for NS4-043.
[0166]
Chemical formula
[0167] 1 1H NMR (500 MHz, CDCl3) δ: 8.55 (d, J = 6.0 Hz, 2H), 8.15 (t, J = 2.0 Hz, 1H), 8.00 (dd, J = 8.0, 2.0 Hz, 1H), 7.66 (dd, J = 8.0, 2.0 Hz, 1H), 7.36 (t, J = 8.0 Hz, 1H), 7.20 (d, J = 6.0 Hz, 2H), 6.44 - 6.42 (m, 2H), 5.77 (s, 1H), 5.17 (s, 1H), 4.78 - 4.67 (m, 2H), 4.24 - 4.12 (m, 2H), 3.60 - 3.50 (m, 2H), 3.30 (s, 3H), 2.41 (s, 3H), 2.37 (s, 3H). ESI-MS m / z: 494.2 [M+H] + .
[0168] <<Synthesis of JYK-004>> The compound represented by the following chemical formula (11) (hereinafter referred to as "JYK-004") was prepared from 2-methoxyethyl 3-aminobut-2-enoate, (E)-3-(pyridin-4-yl)prop-2-en-1-yl 3-oxobutanoate, and 4-nitrobenzaldehyde according to the procedure described for NS4-043.
[0169]
Chemical formula
[0170] 1 1H NMR (500 MHz, CDCl3) δ: 8.54 (d, J = 6.0 Hz, 2H), 8.07 (d, J = 9.0 Hz, 2H), 7.49 (d, J = 9.0 Hz, 2H), 7.16 (d, J = 6.0 Hz, 2H), 6.40 - 6.38 (m, 2H), 5.81 (s, 1H), 5.17 (s, 1H), 4.78 - 4.68 (m, 2H), 4.26 - 4.14 (m, 2H), 3.58 - 3.49 (m, 2H), 3.32 (s, 3H), 2.40 (s, 3H), 2.36 (s, 3H). ESI-MS m / z: 494.2 [M+H] + .
[0171] (Experimental Example 8) <First evaluation of NS4-238> Using the evaluation system constructed in Experimental Example 1, the inhibitory ability of NS4-238 synthesized in Experimental Example 7 on mitochondrial fission was examined.
[0172] NS4-238 was added to the culture medium of neonatal rat cardiomyocytes so that the final concentration was adjusted to 1 μM, the cells were incubated for 1 hour, and further cultured for 16 hours under a hypoxic environment. Next, the cells were stained using MitoTracker Green FM (Thermo Fischer Scientific Inc.) in the same method as described in Experimental Example 1, observed with a fluorescence microscope, and the shape of mitochondria was quantified. Also, for comparison, a group in which nilidipine was added instead of NS4-238 and a group in which dimethyl sulfoxide (DMSO) was added instead of the drug were prepared.
[0173] Figure 8 is a graph showing the measurement results of the ratio of cells having tubular mitochondria. In Figure 8, "CIL" represents the results obtained from nilidipine administration, "NS4-238" represents the results obtained from NS4-238 administration, "DMSO" represents the results obtained from DMSO administration, "N" represents the results obtained from a normoxic environment, and "H" represents the results obtained from a hypoxic environment.
[0174] From the results, it was revealed that NS4-238 significantly inhibits mitochondrial fission under hypoxic stimulation. It was also revealed that the inhibitory ability of NS4-238 on mitochondrial fission is approximately three times higher than that of nilidipine.
[0175] (Experimental Example 9) <Second evaluation of NS4-238> Mitochondrial fission under hypoxic stimulation was examined in Experiment 8. In this experiment, whether mitochondrial fission is promoted by overexpressed Filamin or overexpressed Filamin cardiomyopathy mutant, and the effect of NS4-238 on mitochondrial fission were examined.
[0176] Filamin cardiomyopathy is known to be associated with the A1539T mutation (adenine to thymine substitution at position 1539) in the filamin C gene. We next investigated the effect of the A1545T mutation in the filamin A gene, which is similar to the A1539T mutation in the filamin C gene, on the shape of mitochondria in cardiomyocytes.
[0177] We transduced and overexpressed the wild-type Filamin A gene fused to the mCherry tag or the A1545T mutant Filamin A gene fused to the mCherry tag into mouse cardiac striated muscle cell line, H9c2 cells. For comparison, we also prepared a group transduced and overexpressed the mCherry expression vector.
[0178] The cells were cultured for 24 hours, and cilnidipine or NS4-238 was added to the culture medium at a final concentration of 1 μM, and the cells were cultured for another 24 hours. For comparison, a group was prepared in which DMSO was added instead of the drug.
[0179] Next, the cells were stained with MitoTracker Green FM (Thermo Fischer Scientific Inc.) in the same manner as described in Experimental Example 1. The cells were observed under a fluorescent microscope, and the mitochondrial shape was quantified by image analysis.
[0180] Figure 9(a) is a fluorescence micrograph of the cells. Scale bar = 50 μm. Figure 9(b) is a graph showing the measurement results of the average length of mitochondrial fragments as a result of image analysis of the fluorescence micrograph of Figure 9(a). In Figure 9(b), "*" indicates a significant difference at p<0.05, and "**" indicates a significant difference at p<0.01.
[0181] In Figures 9(a) and 9(b), "DMSO" represents the results obtained from the addition of DMSO, "CIL" represents the results obtained from the addition of cilnidipine, "NS4-238" represents the results obtained from the addition of NS4-238, "mCherry" represents the results obtained from overexpression of mCherry, "mCherry-FLNa WT" represents the results obtained from overexpression of the wild-type filamin A gene fused to the mCherry tag, and "mCherry-FLNa A1545T" represents the results obtained from overexpression of the A1545T mutant of the filamin A gene fused to the mCherry tag.
[0182] The results showed that mitochondrial fission was promoted by overexpression of the wild-type filamin A gene, and was further promoted by overexpression of the A1545T mutant of the filamin A gene.
[0183] It was also revealed that addition of NS4-238 successfully suppressed mitochondrial fission promoted by overexpression of the wild-type filamin A gene or the A1545T mutant of the filamin A gene.
[0184] Furthermore, addition of cilnidipine was unable to suppress mitochondrial fission promoted by overexpression of the wild-type filamin A gene or the A1545T mutant of the filamin A gene.
[0185] (Experimental Example 10) <First evaluation of cilnidipine derivatives> We investigated how the cilnidipine derivatives synthesized in Experimental Example 7 could affect the aging of cardiomyocytes. The aging of cardiomyocytes was evaluated based on the accumulation of p53 protein. More specifically, each cilnidipine and each of the individual compounds synthesized in Experimental Example 7, namely NS4-019, NS4-021 and NS4-043, were added to the culture medium of neonatal rat cardiomyocytes so that the final concentration was adjusted to 1 μM, and the cells were incubated for 1 hour. Next, the cells were subjected to hypoxia-reoxygenation stimulation by culturing them in a hypoxic (1%) environment for 18 hours, followed by culturing them in a normoxic (21%) environment for 18 hours. Next, the cells of each culture were fixed with 4% paraformaldehyde and immunostained with anti-p53 antibody and anti-α-actinin antibody. α-actinin is a marker for cardiomyocytes. The cells of each culture were observed under a fluorescent microscope, and the ratio of p53-accumulating cells to α-actinin-positive cells was determined.
[0186] FIG. 10 is a graph showing the results of measuring the ratio of p53-accumulating cells to α-actinin-positive cells. In FIG. 10, "Nor DMSO" represents the results obtained from cells cultured under normoxia without hypoxia-reoxygenation stimulation with the addition of DMSO, "H / R DMSO" represents the results obtained from cells cultured under hypoxia-reoxygenation stimulation with the addition of DMSO, "H / R CIL" represents the results obtained from cells cultured under hypoxia-reoxygenation stimulation with the addition of cilnidipine, "H / R NS4-019" represents the results obtained from cells cultured under hypoxia-reoxygenation stimulation with the addition of NS4-019, "H / R NS4-021" represents the results obtained from cells cultured under hypoxia-reoxygenation stimulation with the addition of NS4-021, "H / R NS4-043" represents the results obtained from cells cultured under hypoxia-reoxygenation stimulation with the addition of NS4-043, and "**" indicates a significant difference at p<0.01.
[0187] The results revealed that NS4-019 and NS4-043, like cilnidipine, probably exhibited inhibitory effects on cardiomyocyte senescence induced by hypoxia-reoxygenation stimulation. In contrast, NS4-021 was found to have no inhibitory effects on cardiomyocyte senescence induced by hypoxia-reoxygenation stimulation.
[0188] (Experimental Example 11) <Second evaluation of cilnidipine derivatives> Using the evaluation system constructed in Experimental Example 1, the inhibitory effect of the cilnidipine derivatives synthesized in Experimental Example 7 on mitochondrial fission was examined.
[0189] More specifically, first, each cilnidipine and each of the compounds synthesized in Experimental Example 7, i.e., NS4-019, NS4-021 and NS4-043, were added to the culture medium of neonatal rat cardiomyocytes to adjust the final concentration to 1 μM, and the cells were incubated for 1 hour.
[0190] Next, each cell was cultured for another 18 hours in a hypoxic environment. Next, the cells were stained using MitoTracker Green FM (Thermo Fischer Scientific Inc.) in the same manner as described in Experimental Example 1, observed under a fluorescent microscope, and the mitochondrial shape was quantified. For comparison, a group was prepared in which dimethyl sulfoxide (DMSO) was added instead of the drug.
[0191] Fig. 11 is a graph showing the results of measuring the proportion of cells containing vesicular mitochondria. In Fig. 11, "CIL" represents the results obtained from cells to which cilnidipine was added, "*" represents a significant difference at p<0.05, and "**" represents a significant difference at p<0.01.
[0192] The results show that, like cilnidipine, NS4-019 and NS4-043 can significantly inhibit mitochondrial fission under hypoxic stimulation. It was also found that NS4-021 has a tendency to inhibit mitochondrial fission under hypoxic stimulation. In short, the results of Experimental Examples 10 and 11 show that NS4-021 does not show an inhibitory effect on aging of cardiomyocytes under hypoxia-reoxygenation stimulation, but shows a tendency to inhibit mitochondrial fission under hypoxic stimulation.
[0193] (Experimental Example 12) <Third evaluation of cilnidipine derivatives> The calcium channel blocking effect of the cilnidipine derivative synthesized in Experimental Example 7 was examined. More specifically, Neuro-2a cells, which belong to a mouse neuroblastoma cell line, were first cultured in a serum-free culture medium, and Fura 2-AM (Dojindo Laboratories) was added to the culture medium as a calcium ion probe to transduce the cells.
[0194] Next, the culture medium was replaced with HEPES buffered nutrient solution (pH 7.4), each cilnidipine, and the individual compounds synthesized in Experimental Example 7, i.e., NS4-019, NS4-021, NS4-043, NS4-238, and NS4-700, were added to the culture medium to adjust the final concentrations to 0, 1, 10, 100, and 1,000 nM, and the culture medium was incubated for 30 minutes.
[0195] Next, a potassium chloride solution (final concentration 60 mM) was added to give a depolarizing stimulus, and the influx of calcium ions into the cells was observed under a fluorescence microscope.
[0196] Figure 12 is a graph showing the increase in intracellular calcium ion concentration after potassium chloride stimulation. In Figure 12, "CIL" represents the results obtained from cells to which cilnidipine was added, "NS4-238" represents the results obtained from cells to which NS4-238 was added, and "**" represents a significant difference at p<0.01. The horizontal axis indicates the concentration of each compound, and the vertical axis indicates the Δ ratio given by the following formula (F1). Here, the Δ ratio is a value related to the intracellular calcium ion concentration. Δ ratio = (fluorescence intensity at 510 nm when excited at 340 nm) / (fluorescence intensity at 510 nm when excited at 380 nm) ... (F1)
[0197] The results revealed that cilnidipine and NS4-238 exhibited blocking effects on calcium channels, whereas NS4-019, NS4-021, NS4-043, and NS4-700 did not exhibit blocking effects on calcium ion channels.
[0198] (Experimental Example 13) <Fourth evaluation of cilnidipine derivatives> Using the evaluation system constructed in Experimental Example 1, the inhibitory ability of NS4-238 and NS4-700 synthesized in Experimental Example 7 on mitochondrial division was examined.
[0199] More specifically, NS4-238 or NS4-700 was added to the culture medium of neonatal rat cardiomyocytes so that the final concentration was adjusted to 0.3 μM, and the cells were incubated for 1 hour. Next, each cell was cultured for another 18 hours in a hypoxic environment. Next, the cells were stained using MitoTracker Green FM (Thermo Fischer Scientific Inc.) in the same manner as described in Experimental Example 1, observed under a fluorescent microscope, and the shape of mitochondria was quantified. For comparison, a group was prepared in which dimethyl sulfoxide (DMSO) was added instead of the drug.
[0200] Figure 13 is a graph showing the results of measuring the proportion of cells containing vesicular mitochondria. In Figure 13, "DMSO" represents the results obtained from cells to which DMSO was added, "NS4-238" represents the results obtained from cells to which NS4-238 was added, "*" represents a significant difference at p<0.05, and "**" represents a significant difference at p<0.01.
[0201] The results demonstrated that NS4-700, like NS4-238, could significantly inhibit mitochondrial fission under hypoxic stimulation.
[0202] (Experimental Example 14) <Fifth evaluation of cilnidipine derivatives> Using the evaluation system described in the method of Experimental Example 1 in Experimental Example 8, the inhibitory ability of the cilnidipine derivatives synthesized in Experimental Example 7 on mitochondrial fission was examined.
[0203] Figure 14 is a graph showing the results of measuring the proportion of cells having tubular mitochondria. In Figure 14, "Nor DMSO" represents the results obtained from cells cultured under normal oxygen with the addition of DMSO, "DMSO" represents the results obtained from DMSO administration, "Cilnidipine" represents the results obtained from cilnidipine administration, "No. 1" to "No. 9" represent the results obtained from NS4-019, NS4-238, NS4-021, JYK-002, JYK-003, NS4-043, JYK-001, NS4-700, and JYK-004 administration, respectively, "*" represents a significant difference at p<0.05, and "**" represents a significant difference at p<0.01.
[0204] The results showed that NS4-019, NS4-238, NS4-043, and NS4-700 significantly inhibited mitochondrial fission under hypoxic stimulation.
[0205] (Experimental Example 15) <Sixth evaluation of cilnidipine derivatives> According to the method described in Experimental Example 12, the calcium channel blocking effect of the cilnidipine derivative synthesized in Experimental Example 7 was examined.
[0206] Figure 15 is a graph showing the increase in intracellular calcium ion concentration after potassium chloride stimulation. In Figure 15, "Cilnidipine" represents the results obtained from cells to which cilnidipine was added, "No. 1" to "No. 9" represent the results obtained from the administration of NS4-019, NS4-238, NS4-021, JYK-002, JYK-003, NS4-043, JYK-001, NS4-700, and JYK-004, respectively, and "**" indicates a significant difference at p<0.01. The horizontal axis indicates the concentration of each compound, and the vertical axis indicates the Δ ratio given by formula (F1) as in Example 12.
[0207] The results show that cilnidipine and NS4-238 exhibited blocking effects on calcium channels at 1000 nM. [Industrial Applicability]
[0208] According to the present invention, it is possible to provide an inhibitor of Drp1-filamin complex formation.
[0209] Specific Embodiments The present disclosure is illustrated by the following specific embodiments. 1. Compound of formula (I): [ka] (In the formula, The compound is [ka] If other than, R 1 is phenyl substituted with 1 to 3 substituents, each of which is independently NO2, NH2, OH, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 alkoxyalkyl, with the proviso that at least one substituent is NO2 or NH2; R 2 is H, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 alkoxyalkyl; R 3 is H, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 alkoxyalkyl; R 4 is C1-C6 alkyl or C1-C6 haloalkyl; R 5 is phenyl or pyridinyl, wherein the phenyl or pyridinyl is unsubstituted or substituted with 1 to 3 substituents, each of which is independently NO2, NH2, OH, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 alkoxyalkyl; (i) bond a is present and bonds b and c are absent, or (ii) bonds b and c are present and bond a is absent, A is NH when bond a is present, and N when bonds b and c are present; m is an integer from 1 to 4; n is an integer from 1 to 3. Or a pharmacologically acceptable salt thereof, or a solvate thereof. 2. Formula (Ia) [ka] The compound of embodiment 1 having the structure: 3.Formula (Ib) [ka] The compound of embodiment 1 having the structure: 4.R 1 but, [ka] (In the formula, R 1a is NO2 or NH2, R 1b and R 1care each independently H, NO2, NH2, OH, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 alkoxyalkyl. The compound of any one of embodiments 1 to 3, or a pharmacologically acceptable salt or solvate thereof, wherein 5.R 1b and R 1c The compound of embodiment 4, or a pharma- ceutically acceptable salt or solvate thereof, wherein each is independently H, NO2, NH2, OH, C1-C3 alkyl, C1-C3 haloalkyl, or C1-C3 alkoxyalkyl. 6.R 1 but, [ka] or a pharma- ceutical acceptable salt or solvate thereof. 7.R 1 but, [ka] or a pharma- ceutical acceptable salt or solvate thereof. 8.R 1 but, [ka] or a pharma- ceutical acceptable salt or solvate thereof. 9.R 1a The compound of any one of embodiments 4 to 8, or a pharmacologically acceptable salt or solvate thereof, wherein is NO2. 10.R 1a The compound of any one of embodiments 4-8, or a pharma- ceutical acceptable salt or solvate thereof, wherein is NH2. 11.R 2 The compound of any one of embodiments 1-10, or a pharma- ceutical acceptable salt or solvate thereof, wherein is H, C1-C3 alkyl, C1-C3 haloalkyl, or C1-C3 alkoxyalkyl. 12.R 2is C1-C3 alkyl, or a pharma- ceutically acceptable salt or solvate thereof. 13.R 2 is CH3, or a pharma- ceutical acceptable salt or solvate thereof. 14.R 3 The compound of any one of embodiments 1-13, or a pharma- ceutical acceptable salt or solvate thereof, wherein is H, C1-C3 alkyl, C1-C3 haloalkyl, or C1-C3 alkoxyalkyl. 15.R 3 is C1-C3 alkyl, or a pharma- ceutically acceptable salt or solvate thereof. 16.R 3 is CH3, or a pharma- ceutically acceptable salt or solvate thereof. 17.R 4 The compound of any one of embodiments 1-16, or a pharma- ceutically acceptable salt or solvate thereof, wherein is C1-C3 alkyl or C1-C3 haloalkyl. 18.R 4 is C1-C3 alkyl, or a pharma- ceutically acceptable salt or solvate thereof. 19.R 4 is CH3, or a pharma- ceutical acceptable salt or solvate thereof. 20.R 5 The compound of any one of embodiments 1-19, or a pharma- ceutically acceptable salt or solvate thereof, wherein is unsubstituted phenyl or phenyl substituted with 1-3 substituents, each of which is independently NO2, NH2, OH, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 alkoxyalkyl. 21.R 5is unsubstituted phenyl or phenyl substituted with 1 to 3 substituents, each of which is independently NO2, NH2, OH, C1-C3 alkyl, C1-C3 haloalkyl, or C1-C3 alkoxyalkyl, or a pharma- ceutically acceptable salt or solvate thereof. 22.R 5 The compound of embodiment 20, or a pharma- ceutically acceptable salt or solvate thereof, wherein is unsubstituted phenyl. 23.R 5 The compound of any one of embodiments 1 to 19, or a pharma- ceutically acceptable salt or solvate thereof, wherein is unsubstituted pyridinyl or pyridinyl substituted with 1 to 3 substituents, each of which is independently NO2, NH2, OH, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 alkoxyalkyl. 24.R 5 24. The compound of embodiment 23, or a pharma- ceutically acceptable salt or solvate thereof, wherein: is unsubstituted pyridinyl or pyridinyl substituted with 1 to 3 substituents, each of which is independently NO2, NH2, OH, C1-C3 alkyl, C1-C3 haloalkyl, or C1-C3 alkoxyalkyl. 25.R 5 24. The compound of embodiment 23, or a pharma- ceutically acceptable salt or solvate thereof, wherein is unsubstituted pyridinyl. 26.R 5 The compound of any one of embodiments 23-25, or a pharma- ceutically acceptable salt or solvate thereof, wherein pyridinyl is 4-pyridyl. 27.R 5 The compound of any one of embodiments 23-25, or a pharma- ceutically acceptable salt or solvate thereof, wherein pyridinyl is 3-pyridyl. 28.R 5 The compound of any one of embodiments 23-25, or a pharma- ceutically acceptable salt or solvate thereof, wherein pyridinyl is 2-pyridyl. 29. The compound of any one of embodiments 1 to 28, or a pharmacologically acceptable salt or solvate thereof, wherein m is 2. 30. The compound of any one of embodiments 1 to 28, or a pharma- ceutically acceptable salt or solvate thereof, wherein n is 1. 31. A compound of embodiment 2, or a pharmacologically acceptable salt or solvate thereof. (In the formula, R 1 teeth [ka] and In the formula, R 1a is NO2 or NH2, R 2 , R 3 , and R 4 is CH3, R 5 is unsubstituted phenyl or unsubstituted pyridinyl; m is 2, (n is 1). 32.R 5 The compound of embodiment 31, or a pharma- ceutically acceptable salt or solvate thereof, wherein is unsubstituted 4-pyridyl. 33. A compound: [ka] or a pharma- ceutical acceptable salt or solvate thereof. 34. A compound: [ka] or a pharma- ceutical acceptable salt or solvate thereof. 35. A compound: [ka] or a pharma- ceutical acceptable salt or solvate thereof. 36. A compound: [ka] or a pharma- ceutical acceptable salt or solvate thereof. 37. A compound: [ka] or a pharma- ceutical acceptable salt or solvate thereof. 38. A compound: [ka] or a pharma- ceutical acceptable salt or solvate thereof. 39. A compound: [ka] or a pharma- ceutical acceptable salt or solvate thereof. 40. A compound is [ka] or a pharma- ceutical acceptable salt or solvate thereof. 41. A compound: [ka] or a pharma- ceutical acceptable salt or solvate thereof. 42. A compound represented by the following formula (1) or a pharmacologically acceptable salt thereof or a solvate thereof: [ka] (In formula (1), R 1 represents a phenyl group, a 2-pyridyl group, a 3-pyridyl group, or a 4-pyridyl group; R 2 represents a hydrogen atom or an amino group, R 3 represents a hydrogen atom or a nitro group, R 2is a hydrogen atom, R 3 is a nitro group, and R 2 is an amino group, R 3 is a hydrogen atom). 43. In equation (1), (a)R 1 represents a phenyl group, a 2-pyridyl group, a 3-pyridyl group, or a 4-pyridyl group; R 2 represents a hydrogen atom, and R 3 represents a nitro group, or (b)R 1 represents a 2-pyridyl group, a 3-pyridyl group, or a 4-pyridyl group; R 2 represents an amino group, and R 3 43. A compound of embodiment 42, wherein represents a hydrogen atom. 44. In equation (1), R 1 represents a phenyl group, a 2-pyridyl group, a 3-pyridyl group, or a 4-pyridyl group; R 2 represents an amino group, and R 3 43. A compound of embodiment 42, wherein represents a hydrogen atom. 45. A compound represented by the following formula (2) or a pharmacologically acceptable salt thereof or a solvate thereof: [ka] (In formula (2), R 4 represents a phenyl group, a 2-pyridyl group, a 3-pyridyl group, or a 4-pyridyl group; R 5 represents an amino group, and R 6 represents a hydrogen atom). 46. A compound of formula (A): [ka] (In the formula, The compound is [ka] If other than, (a) R is NO2 or NH2, R is in the 2-, 3-, or 4-position of the phenyl ring, and (b) X is CH or N. Or a pharmacologically acceptable salt thereof, or a solvate thereof. 47. A compound of formula (B): [ka] or a pharmacologically acceptable salt thereof or a solvate thereof (In the formula, (a) R is NO2 or NH2, R is in the 2-, 3-, or 4-position of the phenyl ring, and (b) X represents CH or N. 48. The compound of any one of embodiments 1-47 in the form of a pharmacologically acceptable salt, a pharmacologically acceptable salt or a solvate. 49. The compound of embodiment 48, a pharmacologically acceptable salt or solvate, wherein the pharmacologically acceptable salt is hydrochlorate, sulfate, hydrobromate, hydroiodide, phosphate, nitrate, benzoate, methanesulfonate, 2-hydroxyethanesulfonate, p-toluenesulfonate, acetate, propanoate, oxalate, malonate, succinate, glutarate, adipate, tartrate, maleate, fumarate, malate, or mandelate. 50. The compound of any one of embodiments 1-47, in the form of a free base, a pharmacologically acceptable salt, or solvate. 51. The compound, pharmacologically acceptable salt or solvate of any one of embodiments 1-50, not in the form of a solvate. 52. A compound, a pharmacologically acceptable salt or solvate of any one of embodiments 1-51, having mitochondrial fission inhibitory activity. 53. The compound of embodiment 52, a pharmacologically acceptable salt or solvate thereof, wherein the mitochondrial fission inhibitory activity is at least 50% of the mitochondrial fission inhibitory activity of cilnidipine, for example, as determined by the evaluation system of Experimental Example 1. 54. The compound, pharmacologically acceptable salt or solvate of embodiment 52, having a mitochondrial fission inhibitory activity that is at least 75% of the mitochondrial fission inhibitory activity of cilnidipine, for example, as determined by the evaluation system of Experimental Example 1. 55. The compound, pharmacologically acceptable salt or solvate of embodiment 52, wherein the mitochondrial fission inhibitory activity is at least 90% of the mitochondrial fission inhibitory activity of cilnidipine, for example, as determined by the evaluation system of Experimental Example 1. 56. The compound of embodiment 52, a pharmacologically acceptable salt or solvate thereof, having a mitochondrial fission inhibitory activity at least equal to that of cilnidipine, for example as determined by the evaluation system of Experimental Example 1. 57. A compound, pharmacologically acceptable salt or solvate of any one of embodiments 52 to 56, having a mitochondrial fission inhibitory activity of up to 300% of the mitochondrial fission inhibitory activity of cilnidipine, as determined, for example, by the evaluation system of Experimental Example 1. 58. A compound, pharmacologically acceptable salt or solvate of any one of embodiments 52 to 56, having a mitochondrial fission inhibitory activity of up to 200% of the mitochondrial fission inhibitory activity of cilnidipine, as determined, for example, by the evaluation system of Experimental Example 1. 59. A compound, pharmacologically acceptable salt or solvate of any one of embodiments 52 to 56, having a mitochondrial fission inhibitory activity of up to 150% of the mitochondrial fission inhibitory activity of cilnidipine, as determined, for example, by the evaluation system of Experimental Example 1. 60. The compound, pharmacologically acceptable salt, or solvate of any one of embodiments 1-59, having reduced calcium channel blocking activity compared to cilnidipine. 61. The compound of embodiment 60, a pharmacologically acceptable salt or solvate thereof, having a calcium channel blocking activity that is 75% or less than that of cilnidipine, for example as determined by the rating system of Example 12. 62. The compound of embodiment 60, a pharmacologically acceptable salt or solvate thereof, having a calcium channel blocking activity that is 50% or less than that of cilnidipine, for example as determined by the rating system of Example 12. 63. The compound of embodiment 60, a pharmacologically acceptable salt or solvate thereof, having a calcium channel blocking activity that is 25% or less than that of cilnidipine, for example as determined by the rating system of Example 12. 64. The compound or pharmacologically acceptable salt or solvate of embodiment 60, having a calcium channel blocking activity that is 10% or less than that of cilnidipine, for example as determined by the rating system of Example 12. 65. A pharmaceutical composition comprising a compound of any one of embodiments 1-64, a pharmacologically acceptable salt or solvate, and one or more pharma- ceutically acceptable carriers. 66. The pharmaceutical composition of embodiment 65, wherein the one or more pharma- ceutically acceptable carriers comprise a base. 67. The pharmaceutical composition of embodiment 66, wherein the base comprises purified water, titanium oxide, carnauba wax, synthetic squalane, crotamiton, or gelatin. 68. The pharmaceutical composition of any one of embodiments 65-67, wherein the one or more pharma- ceutically acceptable carriers comprises a binder. 69. The pharmaceutical composition of embodiment 68, wherein the binder comprises ethyl cellulose, glycerin, or methacrylic acid copolymer S. 70. The pharmaceutical composition of any one of embodiments 65-69, wherein the one or more pharma- ceutically acceptable carriers comprise an excipient. 71. The pharmaceutical composition of embodiment 70, wherein the excipients are microcrystalline cellulose, croscarmellose sodium, magnesium stearate, and hypromellose, stabilizers such as gum arabic, magnesium aluminometasilicate, povidone, benzyl alcohol, sodium acetate, or magnesium stearate. 72. The pharmaceutical composition of any one of embodiments 65-71, wherein the one or more pharma- ceutically acceptable carriers comprises a plasticizer. 73. The pharmaceutical composition of embodiment 72, wherein the plasticizer is Macrogol 400 or Macrogol 6000. 74. The pharmaceutical composition of any one of embodiments 65-73, wherein the one or more pharma- ceutically acceptable carriers comprise a solubilizer. 75. The pharmaceutical composition of embodiment 74, wherein the solubilizers are benzyl benzoate and benzyl alcohol. 76. The pharmaceutical composition of any one of embodiments 65-75, which does not contain any active pharmaceutical ingredient other than the compound, pharmacologically acceptable salt or solvate of any one of embodiments 1-64. 77. The pharmaceutical composition of any one of embodiments 65-75, which is substantially free of cilnidipine. 78. The pharmaceutical composition of any one of embodiments 65-77, wherein the compound, pharmacologically acceptable salt, or solvate of any one of embodiments 1-64 is at least 90% pure. 79. The pharmaceutical composition of any one of embodiments 65-77, wherein the compound, pharmacologically acceptable salt, or solvate of any one of embodiments 1-64 is at least 95% pure. 80. The pharmaceutical composition of any one of embodiments 65-79, which is in an oral dosage form. 81. The pharmaceutical composition of embodiment 80, in the form of a pill, tablet, capsule, elixir or microcapsule. 82. The pharmaceutical composition of any one of embodiments 65-79, comprising at least 1 mg of a compound, pharmacologically acceptable salt or solvate of any one of embodiments 1-64. 83. The pharmaceutical composition of any one of embodiments 65-79, comprising at least 2 mg of a compound, pharmacologically acceptable salt or solvate of any one of embodiments 1-64. 84. The pharmaceutical composition of any one of embodiments 65-79, comprising at least 5 mg of a compound, pharmacologically acceptable salt or solvate of any one of embodiments 1-64. 85. The pharmaceutical composition of any one of embodiments 65-79, comprising at least 10 mg of a compound, pharmacologically acceptable salt or solvate of any one of embodiments 1-64. 86. The pharmaceutical composition of any one of embodiments 65-85, comprising up to 20 mg of a compound, pharmacologically acceptable salt or solvate of any one of embodiments 1-64. 87. The pharmaceutical composition of any one of embodiments 65-85, comprising up to 25 mg of a compound, pharmacologically acceptable salt or solvate of any one of embodiments 1-64. 88. The pharmaceutical composition of any one of embodiments 65-85, comprising up to 50 mg of a compound, pharmacologically acceptable salt or solvate of any one of embodiments 1-64. 89. A dynamin-related protein 1 (Drp1)-filamin complex formation inhibitor comprising, as an active ingredient, a compound, pharmacologically acceptable salt, or solvate of any one of embodiments 1 to 64. 90. A compound of any one of embodiments 1 to 64, a pharmacologically acceptable salt or solvate, a pharmaceutical composition of any one of embodiments 65 to 88, or a (Drp1)-filamin complex formation inhibitor of embodiment 89, for use as a prophylactic or therapeutic agent for a disease caused by impaired Drp1 function. 91. A compound of any one of embodiments 1 to 64, a pharmacologically acceptable salt or solvate, a pharmaceutical composition of any one of embodiments 65 to 88, or a (Drp1)-Filamin complex formation inhibitor of embodiment 89 for use as a preventive or therapeutic agent for chronic heart failure. 92. A compound of any one of embodiments 1 to 64, a pharmacologically acceptable salt or solvate, a pharmaceutical composition of any one of embodiments 65 to 88, or a (Drp1)-filamin complex formation inhibitor of embodiment 89 for use as a prophylactic or therapeutic agent for amyotrophic lateral sclerosis. 93. A compound of any one of embodiments 1 to 64, a pharmacologically acceptable salt or solvate, a pharmaceutical composition of any one of embodiments 65 to 88, or a (Drp1)-filamin complex formation inhibitor of embodiment 89 for use as a prophylactic or therapeutic agent for inflammatory bowel disease. 94. Diabetes, optional (a) type 1 diabetes, or (b) Type 2 diabetes A compound of any one of embodiments 1 to 64, a pharmacologically acceptable salt or solvate, a pharmaceutical composition of any one of embodiments 65 to 88, or a (Drp1)-filamin complex formation inhibitor of embodiment 89 for use as a prophylactic or therapeutic agent for 95. A method for treating a disease caused by impaired Drp1 function, comprising administering to a subject in need thereof a therapeutically effective amount of a compound, a pharmacologically acceptable salt or solvate of any one of embodiments 1-64, a pharmaceutical composition of any one of embodiments 65-88, or a (Drp1)-Filamin complex formation inhibitor of embodiment 89. 96. A method for treating chronic heart failure, comprising administering to a subject in need thereof a therapeutically effective amount of a compound, a pharmacologically acceptable salt or solvate of any one of embodiments 1-64, a pharmaceutical composition of any one of embodiments 65-88, or a (Drp1)-Filamin complex formation inhibitor of embodiment 89. 97. A method for treating amyotrophic lateral sclerosis, comprising administering to a subject in need thereof a therapeutically effective amount of a compound, a pharmacologically acceptable salt or solvate of any one of embodiments 1-64, a pharmaceutical composition of any one of embodiments 65-88, or a (Drp1)-Filamin complex formation inhibitor of embodiment 89. 98. A method for treating inflammatory bowel disease, comprising administering to a subject in need thereof a therapeutically effective amount of a compound, a pharmacologically acceptable salt or solvate of any one of embodiments 1-64, a pharmaceutical composition of any one of embodiments 65-88, or a (Drp1)-Filamin complex formation inhibitor of embodiment 89. 99. A method for treating diabetes, e.g. type 1 diabetes or type 2 diabetes, comprising administering to a subject in need thereof a therapeutically effective amount of a compound, a pharmacologically acceptable salt or solvate of any one of embodiments 1-64, a pharmaceutical composition of any one of embodiments 65-88, or a (Drp1)-Filamin complex formation inhibitor of embodiment 89. 1'. A dynamin-related protein 1 (Drp1)-filamin complex formation inhibitor comprising, as an active ingredient, a compound represented by the following formula (1) or a pharmacologically acceptable salt thereof, or a solvate thereof: [ka] (In formula (1), R 1 represents a phenyl group, a 2-pyridyl group, a 3-pyridyl group, or a 4-pyridyl group; R 2 represents a hydrogen atom or an amino group, R 3 represents a hydrogen atom or a nitro group, R 2 is a hydrogen atom, R 3 is a nitro group, and R 2 is an amino group, R 3 is a hydrogen atom). 2'. In formula (1), R 1 represents a phenyl group, a 2-pyridyl group, a 3-pyridyl group, or a 4-pyridyl group; R 2 represents a hydrogen atom, and R 3 represents a nitro group, or R 1 represents a 2-pyridyl group, a 3-pyridyl group, or a 4-pyridyl group; R 2 represents an amino group, and R 3 The Drp1-filamin complex formation inhibitor according to embodiment 1', wherein represents a hydrogen atom. 3'. In formula (1), R 1 represents a phenyl group, a 2-pyridyl group, a 3-pyridyl group, or a 4-pyridyl group; R 2 represents an amino group, and R 3 The Drp1-filamin complex formation inhibitor according to embodiment 1', wherein represents a hydrogen atom. 4'. A Drp1-filamin complex formation inhibitor according to any one of embodiments 1' to 3', which is a prophylactic or therapeutic agent for a disease caused by Drp1 dysfunction. 5'. The Drp1-Filamin complex formation inhibitor according to embodiment 4', wherein the disease is chronic heart failure, amyotrophic lateral sclerosis, inflammatory bowel disease or type 2 diabetes. 6'. A pharmaceutical composition for inhibiting Drp1-filamin complex formation, comprising a Drp1-filamin complex formation inhibitor described in any one of embodiments 1' to 5', and a pharma- ceutically acceptable carrier. 7'. A compound represented by the following formula (2) or a pharmacologically acceptable salt thereof or a solvate thereof: [ka] (In formula (2), R 4 represents a phenyl group, a 2-pyridyl group, a 3-pyridyl group, or a 4-pyridyl group; R 5 represents an amino group, and R 6 represents a hydrogen atom).
Claims
1. A preventive or therapeutic drug for chronic heart failure, comprising as an active ingredient a compound represented by the following formula (3) or a pharmacologically acceptable salt thereof, or a solvate thereof: 【Chemistry 1】
2. A preventive or therapeutic drug for chronic heart failure, comprising as an active ingredient a compound represented by the following formula (6) or a pharmacologically acceptable salt thereof, or a solvate thereof: 【Chemistry 2】
3. A preventive or therapeutic drug for chronic heart failure, comprising as an active ingredient a compound represented by the following formula (4) or a pharmacologically acceptable salt thereof, or a solvate thereof: 【Chemistry 3】
4. A preventive or therapeutic drug for chronic heart failure, comprising as an active ingredient a compound represented by the following formula (5) or a pharmacologically acceptable salt thereof, or a solvate thereof: 【Chemistry 4】
5. A preventive or therapeutic drug for inflammatory bowel disease, comprising as an active ingredient a compound represented by the following formula (4) or a pharmacologically acceptable salt thereof, or a solvate thereof: 【Chemistry 5】
6. A preventive or therapeutic drug for type 1 diabetes or type 2 diabetes, comprising as an active ingredient a compound represented by the following formula (4) or a pharmacologically acceptable salt thereof, or a solvate thereof: 【Chemistry 6】
Citation Information
Patent Citations
1,4-dihydropyridine derivative
JP1990121967A
Pyridyl compound and pharmaceutical composition containing same
JP2001519415A
Drp1 POLYMERIZATION INHIBITOR
WO2016080516A1
